Drug intelligence / Profile preview

RT306

Development stage: Preclinical
Lead developer: Revio Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

RT306 is a preclinical-stage oral fixed-dose combination (FDC) capsule being developed by Revio Therapeutics. It is part of the company's reformulation pipeline, which focuses on enhancing the delivery and efficacy of proven drugs through optimized delivery systems. RT306 is specifically targeted toward the treatment of inflammatory conditions. As a fixed-dose combination, it likely incorporates two or more active pharmaceutical ingredients into a single oral capsule to improve therapeutic outcomes, simplify dosing regimens, or enhance patient compliance.

Beyond the preview

Go deeper on RT306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT306.

Explore the full profile